Compositions and methods for the treatment or prevention of oxalate-related disorders
AssigneeOxthera Intellectual Property AB
InventorsElisabeth Lindner, Maria Åkerman, Anna Sjögren, Orla McCallion
Life of this patent
Estimating the term…
Abstract
The present disclosure is related to pharmaceutical compositions and methods for treating and/or preventing oxalate-related disorders. More particularly, the present disclosure pertains to compositions comprising an oxalate-degrading bacteria Oxalobacter formigenes particularly suitable for the treatment and/or prevention of late stage hyperoxaluria characterized by high plasma-oxalate levels and a progressing decrease in kidney function.
Claims20
An enteric-coated capsule for oral administration of Oxalobacter formigenes to a subject in need thereof, comprising a pharmaceutical composition comprising:
- (i) 10% to 25% by dry weight of Oxalobacter formigenes;
- (ii) 50% to 65% by dry weight of sucrose;
- (iii) about 10% to 30% by dry weight of one or more cryopreserving agents and/or excipients;
- wherein said enteric-coated capsule delivers Oxalobacter formigenes to the small intestine and/or to the ileum, and
- wherein the in vitro oxalate-degrading activity of the Oxalobacter formigenes present in said enteric-coated capsule is no less than (NLT) 100 mmol/capsule/19 hours.
Dependencies are inferred from the claim text.